A team of European researchers has pub­lished results of a major clinical trial investi­gat­ing the efficacy and safety of Pomalyst (poma­lido­mide, Imnovid) and dexa­metha­sone in multiple myeloma patients who have had many prior ther­apies.

Results of the trial, known as the STRATUS (MM-010) study, have pre­vi­ously been presented at several major medical meetings. This is the first time, how­ever, that the results have been summarized in a journal article.

The new efficacy and safety results are in line with previously published results of other trials testing the combination of Pomalyst …

Hallo Myelomwelt.

Wir sind immer noch dabei, die jüngste Welle an Forschungsartikeln über das multiple Myelom aufzuarbeiten und freuen uns, dass es endlich Frühling wird. Wichtiger ist jedoch, dass unsere heutige Titelgeschichte die angenehme Seite von Mutter Natur widerspiegelt.

Genauer gesagt gibt es aktualisierte Daten über das Myelomüberleben in den Vereinigten Staaten, und es sind gute Nachrichten.

Es ist nur eine jährliche Aktualisierung - ein einzelner neuer Wert für das Fünfjahresüberleben vom Zeitpunkt der Diagnose. Und er ist für Patienten, die 2008 diagnostiziert wurden – das neueste Jahr, für das umfangreiche Daten …

Good morning, myeloma world.

It's a glorious spring morning here at Myeloma Morning Headquarters. The sun is coming up in the midst of a clear blue sky, and the cherry tree out front is bursting with blossoms.

In other words, it's a great day to get excited about new multiple myeloma research and other myeloma-related developments.

First, we take a look at a new study by researchers at the John Theurer Cancer Center (JTCC) in New Jersey. They examine whether Pomalyst (pomalidomide, Imnovid) can be used safely in relapsed myeloma patients with …

Results featured at the 57th Annual American Society of Hematology Meeting and Exposition:

• 72 per­cent of re­lapsed or refractory multiple myeloma patients treated with dara­tu­mu­mab com­bi­na­tion ther­apy did not progress or relapse after 18 months of treat­ment (GEN 503)
• Daratumumab in com­bi­na­tion with poma­lido­mide and dexa­meth­a­sone produced rapid, deep and durable responses in re­lapsed and refractory multiple myeloma patients who had received at least two (median of 3.5) prior lines of ther­apy, in­­clud­ing two or more consecutive cycles of lena­lido­mide and bor­tez­o­mib, and were refractory to their last line of treat­ment (MMY1001 Phase1b)
• Single-agent dara­tu­mu­mab dem­onstrated a median over­all survival of 20 months in heavily pre-treated re­lapsed and refractory multiple myeloma patients who have exhausted other approved treat­ment options. A partial response or better was achieved by 31 per­cent of patients, and 83 per­cent achieved stable disease or better (GEN 501 & MMY2002)

Beerse, Belgium (Press Release) – Janssen-Cilag Inter­na­tional NV announced new data from the ongoing Phase 1/2 GEN503 inves­ti­ga­tional study showing the human CD38-directed mono­clonal anti­body dara­tumumab, in com­bi­na­tion with lena­lido­mide and dexa­meth­a­sone, yielded an over­all response rate (ORR) of 81 per­cent in re­lapsed or refractory multiple myeloma patients who had received a median of two prior ther­a­pies. After 18 months of treat­ment, investigators observed an over­all survival (OS) rate of 90 per­cent, with 72 per­cent …

Summit, NJ (Press Release) – Celgene Corpo­ra­tion (NASDAQ:CELG) today announced it has fulfilled the accelerated approval require­ments for POMALYST® (poma­lido­mide) based on results from MM-003, an inter­na­tional phase III study of POMALYST plus low-dose dex­a­meth­a­sone versus high-dose dex­a­meth­a­sone in re­lapsed / refractory multiple myeloma patients. POMALYST, in com­bi­na­tion with dex­a­meth­a­sone is ap­proved for patients with multiple myeloma who have received at least two prior ther­a­pies in­­clud­ing lena­lido­mide and a pro­te­a­some inhibitor and have dem­onstrated disease pro­gres­sion on or within 60 days of com­ple­tion of the last ther­apy.

"There remains a sig­nif­i­cant unmet need …

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions through­out the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immuno­therapeutic ap­proach to treating cancer known as …

The Beacon is pleased to introduce our newest myeloma thought leader col­um­nist, Dr. Ravi Vij. Every three months, Dr. Vij will share with us a new edition of “The Myeloma Quiz,” which will test your knowledge and under­standing of the myeloma-related research published during the pre­vi­ous several months.

We hope you will join us in welcoming Dr. Vij to the Beacon community, and in thank­ing him for sharing with us his valuable perspectives.

The relentless grind in the battle against myeloma continues. The last several months have seen some major presentations …